The European Vaccine Initiative (EVI) proudly participated in the Product Development Partnerships (PDP) IV Annual Meeting on November 12th, 2024, an event bringing together global health organisations dedicated to developing innovative solutions for infectious and neglected diseases.
November 2024
At this year’s meeting, Prof. Ole Olesen, EVI’s Executive Director, highlighted EVI’s leading work on placental malaria, a life-threatening condition affecting pregnant women and their unborn children in malaria-endemic regions.
Our contributions focus on activities funded by The Netherlands Enterprise Agency (RVO):
• Cutting-edge Research: development and clinical testing of leading vaccine candidates against malaria during pregnancy
• Targeted Innovation: leveraging new technologies (2nd generation vaccine candidates) and collaborations to accelerate the pathway from discovery to delivery, ensuring timely solutions for at-risk populations.
• Global Impact: aligning with the PDP model, by partnering up with researchers, funders, and public health leaders to align research efforts and ensure equitable access to life-saving solutions.
Placental malaria remains a significant global health challenge, needing urgent attention and action. EVI’s pioneering research aims to disrupt the cycle of transmission from mother to foetus, safeguarding the health of mothers and babies and contributing to the fight against malaria worldwide.
We were honoured to present these advancements at the PDP IV Annual Meeting, where collaboration among public and private sectors, academia, and NGOs drives progress toward eliminating preventable infectious diseases. Together, we are fostering innovation and hope for a healthier future.
Read the full brochure:
Comments